Enliven Therapeutics (NASDAQ:ELVN) Reaches New 1-Year High – Here’s Why

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) hit a new 52-week high during mid-day trading on Friday . The stock traded as high as $31.76 and last traded at $30.05, with a volume of 4931441 shares. The stock had previously closed at $27.25.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. Wall Street Zen downgraded Enliven Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Wednesday, January 21st. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $41.00.

Enliven Therapeutics Stock Down 3.6%

The firm’s fifty day simple moving average is $27.63 and its 200-day simple moving average is $22.47. The company has a market cap of $1.73 billion, a PE ratio of -15.57 and a beta of 0.33.

Enliven Therapeutics (NASDAQ:ELVN) last announced its earnings results on Tuesday, March 3rd. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.06). On average, analysts predict that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Insiders Place Their Bets

In other news, CFO Benjamin Hohl sold 10,000 shares of the stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $29.58, for a total transaction of $295,800.00. Following the completion of the transaction, the chief financial officer directly owned 51,000 shares in the company, valued at approximately $1,508,580. This represents a 16.39% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, COO Anish Patel sold 48,300 shares of the stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $27.99, for a total value of $1,351,917.00. Following the transaction, the chief operating officer owned 215,011 shares of the company’s stock, valued at approximately $6,018,157.89. This trade represents a 18.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 232,180 shares of company stock worth $6,217,033 in the last quarter. Company insiders own 25.90% of the company’s stock.

Institutional Trading of Enliven Therapeutics

Several institutional investors have recently added to or reduced their stakes in ELVN. Mirae Asset Global Investments Co. Ltd. boosted its stake in Enliven Therapeutics by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after acquiring an additional 594 shares during the last quarter. BNP Paribas Financial Markets increased its position in shares of Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after purchasing an additional 930 shares during the last quarter. Quantbot Technologies LP raised its stake in shares of Enliven Therapeutics by 47.1% in the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after purchasing an additional 1,434 shares in the last quarter. AlphaQuest LLC acquired a new stake in shares of Enliven Therapeutics in the 3rd quarter valued at about $96,000. Finally, Tower Research Capital LLC TRC lifted its position in shares of Enliven Therapeutics by 194.3% during the second quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company’s stock worth $106,000 after purchasing an additional 3,490 shares during the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.